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Abstract 
BACKGROUND: MicroRNAs (miRNAs) are small, non-coding RNAs that are important for post-transcriptional 
gene regulation in both healthy and morbid conditions. Numerous miRNAs promote tumorigenesis, while others 
have a tumour suppressive effects. Acute myeloid leukaemia (AML) is a heterogeneous group of genetically 
diverse hematopoietic malignancies with variable response to treatment.  
AIM: Our study aimed to investigate the possible role of miR-150 in de novo adult AML and the impact of its level 
on survival, and we used in the silicon analysis to predict the main target genes involved in miR-150 mediated 
cancer pathway.  
MATERIAL AND METHODS: We evaluated miR-150 expression profiling assay using TaqMan primer probes 
Real time-PCR in the plasma of 50 adult AML patients, before the start of treatment and at day 28 of treatment, 
along with 20 normal adult control samples. miR-16 was used as an endogenous reference for standardisation. 
Follow-up of patients during treatment at day 28 of induction chemotherapy and after one year was done.  
RESULTS: In this study, we found a significantly lower level of miR-150 in AML patients when compared to 
controls (p = 0.005) with 0.62 fold change than in healthy controls. Patients were divided into two groups: the low 
miR-150 group (miR-150 < 1) and the high miR-150 group (miR-150 > 1). A statistically significant difference was 
found between the two groups regarding initial total leukocytic count and initial PB blast count while for the TLC, 
HB and PLT count at follow up. No difference in the overall survival between the low and the high miR-150 groups 
could be demonstrated.  
CONCLUSION: Our results suggest that miR-150 functions as a tumour suppressor and gatekeeper in inhibiting 
cell transformation and that its downregulation is required for leukemogenesis. 
 
 
 
 
 
 
 
Introduction 
 
Acute myeloid leukaemia (AML) is a clonal 
disorder of hematopoietic progenitor cells which is 
characterised by diverse heterogeneity regarding 
genotypic, phenotypic and clinical features [1], [2]. 
AML is the most common acute leukaemia in adult 
patients and can arise “de novo” or as a secondary 
event [3]. Among the genetic aberrations that control 
disease development, there are microRNAs. 
MicroRNAs (miRNAs) are short non-coding 
RNAs (~20-24 nucleotides) that are involved in post-
transcriptional regulation of gene expression in 
multicellular organisms. This is achieved by affecting 
both the stability and translation of mRNAs [4]. 
miRNAs play an important role in many biological 
processes in the body such as cell growth, 
proliferation, differentiation, and apoptosis. They also 
act as both oncogenes and tumour suppressors 
contributing to a malignant transformation in solid and 
haematological tumours, including AML [5]. 
Basic Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
1994                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
MiR-150 is a family of microRNA precursors found 
in mammals, including humans. The mature miRNA 
sequence is a 22 nucleotide, which is excised from 
the precursor hairpin by the enzyme Dicer [6]. This 
sequence then associates with RISC (RNA‐induced 
silencing complex), that directly bind to the potential 
target site in the 3' untranslated region (3'UTRs) of 
specific target mRNA, leading to the repression of 
mRNA translation or the degradation of target mRNAs 
[7]. In normal hematopoiesis, miR-150 regulates 
genes whose downstream products encourage the 
differentiation of stem cells towards becoming 
megakaryocytes rather than erythrocytes [8]. It is also 
thought that together with miR-155, control B and T 
cell differentiation [9].  
MiR-150 has been linked to the development 
of some cancers [10]. Mraz et al. reported that the 
expression of miR-150 was shown to regulate levels 
of GAB1 and FOXP1 proteins in malignant and normal 
B cells, which influences their BCR signalling [11]. 
Aberrant miRNA expression is a feature of 
different cancers including haematological 
malignancies. In a study by Morris et al., they 
identified that the expression of miR-150 is low or 
absent in blastic crisis (BC) of chronic myeloid 
leukaemia (CML) and acute myeloid leukaemia (AML) 
patients’ samples and also in cell lines [12]. They 
found that the expression of miR-150 in AML cell 
lines, CD34+ progenitor cells from healthy individuals 
and primary BC CML and AML patients’ samples at 
levels similar to miR-150 expression in normal bone 
marrow promotes myeloid differentiation of these 
cells.  
They also reported that in AML cell lines, 
differentiation of miR-150 expressing cells occurs 
independently of retinoic acid receptor α (RARA) 
signalling and that the high throughput gene 
expression profiling (GEP) studies of the AML cell 
lines HL60, PL21 and THP-1 suggest that activation of 
CEPBA, CEBPE and cytokines associated with 
myeloid differentiation in miR-150 expressing cells, as 
compared to control cells, contributes to myeloid 
differentiation. They concluded from these data that 
miR-150 promotes myeloid differentiation, a 
previously uncharacterized role for this miRNA and 
that absent or low miR-150 expression contributes to 
down-regulated myeloid differentiation in acute 
leukaemia cells [12]. 
From two genomes wide large-scale miRNA 
expression profiling assays of various subtypes of 
primary AML samples and normal controls, Jiang et 
al., [13] identified miR-150 as one of the most 
significantly and consistently down-regulated miRNAs 
in most of the AML cases they have studied. They 
furthermore confirmed this significant down-regulation 
by a subsequent study [14].  
 
 
Material and Methods  
 
This is a matched case-control study included 
50 adults de novo AML cases that were recruited from 
the Medical Oncology Department of the National 
Cancer Institute, Cairo University, Egypt, from 
January 2015 to March 2016. As well as 20 healthy 
volunteers were included as a control group. Approval 
from the Ethical Committee was obtained (Medical 
Ethical Research Committee—National Research 
Centre, Number P100510) to carry over this study and 
informed consents were signed by the patients by the 
Helsinki declaration. The demographic characteristics 
were documented at a presentation in addition to 
morphological, cytochemical, immunophenotypic and 
genetic analyses which were done at initial diagnosis. 
The follow-up data including the response to 
treatment and survival were documented for all 
patients.  
 
Sampling and Extraction of micro-RNA 
Two ml of peripheral blood were collected on 
EDTA from the newly diagnosed adult AML cases (n = 
50) before starting therapy, follow up samples were 
collected at day 28 of treatment for 31 of them. 
Samples were also collected from the twenty healthy 
adults. 
miRNA was isolated from plasma samples 
using miRNeasy Mini Kit (Cat number# 217004, 
Qiagen, USA) as recommended by the manufacturer’s 
instructions, the purity and the concentration of the 
purified miRNA was detected using 
spectrophotometer Nano-drop (Maestrogen, Taiwan, 
MN-913) and stored at -80 ˚C till further assessments.  
 
Detection of miRNA expression using 
Real-Time PCR 
Gene-specific complementary DNA (cDNA) 
was prepared from miRNA by using reversing 
TaqMan microRNA RT-Kit, Cat number # 4366596, 
(Applied Biosystems, Foster City, CA, USA), 
according to the manufacturer’s instructions. miRNA 
expression for enrolled samples was quantified using 
TaqMan 2x universal master mix II Cat number # 
4440043, (Applied Biosystems, Foster City, CA, USA) 
and TaqMan microRNA Assay Mix containing PCR 
primers and TaqMan probes for miR-150. MiR-16 was 
used as endogenous control for normalisation. 
Fluorescence was acquired and detected by ABI step 
one- Applied Biosystems. To determine miRNA 
relative expression, it was reported as fold change 
(ΔCt and ΔΔCt calculations). 
The overall survival (OS) was calculated from 
the date of diagnosis to the date of death or last follow 
up visit. Disease-free survival was calculated from the 
date of complete remission to the date of relapse, 
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death or last follow up visit. 
 
Statistical analysis 
The data were presented as mean ± SD or 
median. The results were calculated using the 
Student’s t-test, 
2
, paired sample T-test, Mann-
Whitney U test or Kruskal-Wallis test where 
appropriate. Categorical variables were described with 
count and percentage. Kaplan-Meier method was 
used to calculate the survival rates and the log-rank 
test was used to test the significance in the difference 
in the patients’ survival. Statistical analyses were 
performed using SPSS software (version 16.0 for 
Windows; SPSS INC., Chicago, IL, USA) where P 
values were two-tailed and considered statistically 
significant when less than 0.05. 
 
Bioinformatics analysis 
In a silico analysis for the miR-150 was 
performed to find target genes regulated by miR-150 
and identifying the possible cellular pathways in which 
these target genes are involved. The miRNA target 
genes were predicted with the miRBase 
(www.mirbase.org). MicroRNA target gene analysis 
was performed using miRWalk 2.0 server 
[http://mirwalk.uni-hd.de/] which is a database that 
gives both predicted and experimentally validated 
miRNA-targets [15], [16]. The predicted target genes 
were obtained with cut off p-value 0.05, in addition to 
the validated ones. Both predicted and validated 
target genes were combined to furtherly undergo 
functional enrichment analysis. 
Functional enrichment analysis for the miRNA 
target genes was done using the DAVID server 
[Database for Annotation, Visualization and Integrated 
Discovery], (https://david.ncifcrf.gov) [17], [18]. 
Pathway enrichment analyses of the predicted miRNA 
target genes were performed with KEGG pathway 
(www.genome.jp/kegg) [19]. 
 
 
Results 
 
We included in our study 50 de novo adult 
AML patients (before starting treatment and at D28 of 
treatment). Thirty two of them were males (64%) and 
18 were females (36%); mean age was (37.48 ± 
12.38), as well as 20 age and sex-matched controls. 
We estimated the expression level of miR-150 in both 
the patient group initially and at D28 and the control 
group using TaqMan primer-probe assay Real Time 
PCR. We also evaluated parameters of clinical 
importance in the AML group such as; total leukocytic 
count (TLC), haemoglobin concentration (HB), platelet 
count (PLTs), bone marrow (BM) cellularity and blast 
% in both peripheral blood (PB) and bone marrow, 
initially and at D28. Immunophenotypic markers, 
cytogenetics and FLT-3 mutational status, were 
investigated too.  
The expression level of miR-150 in both the 
patients group initially and the control group was 
estimated using Real-Time PCR. A significant 
difference between the initial level of miR-150 in 
patients and controls (p = 0.005) was found.  
Plasma initial miR-150 was down-regulated in 
adult AML with 0.62 fold change than in healthy 
controls as demonstrated in Figure 1. A statistically 
significant lower values of relative expression of miR-
150 in patients initially and at D28 compared to 
controls (p = 0.004) (Fig. 2). 
 
Figure 1: Relative initial plasma miR-150 levels in adult AML patient 
and control population. Expression levels of miR-150 were 
normalised to miR-16. Data were represented as the median value, 
and the Mann-Whitney U test was used to define statistical 
significance 
 
We followed up our patients for their miR-150 
at D28 of treatment. We found a significant decrease 
in the TLC and increase PLT count when measured 
initially in patients compared to its measurement at 
D28. No significant difference was found regarding HB 
concentration and miR-150 level (Table 1).  
 
Figure 2: Relative plasma miR-150 levels in AML patients initially, at 
D28 of treatment and control population. Expression levels of miR-
150 were normalised to miR-16. Data were represented as the 
median value, and Kruskal Wallis Test was used to define statistical 
significance 
P = 0 .005 
 
P = 0 .004 
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Table 1: Demographic and clinical characteristics of patients 
before treatment and at D28 of treatment 
Parameters Initial value D28 value P value 
miR-150 
n=31 
1.1 ± 1.18 0.85 ± 0.92 0.3 
TLC x10
9
/L 34.5 ± 49.05 3.8 ± 4.1 0.001** 
HB gm/dL 7.9 ± 1.5 7.9 ± 1.2 0.9 
PLTs x10
9
/L 57.96 ± 68.3 1.85x10
2 
± 172. <0.001** 
TLC: total leucocytic count, HB: haemoglobin, PLTs: platelet count, **highly significant 
statistical difference. 
 
AML patients who achieved complete 
remission (CR) after induction chemotherapy at D28 
were 32 cases (64%), while 7 cases were relapsed 
(21%) later on. No statistically significant difference 
was found in the relative expression of miR-150 
before and after treatment in patients undergo CR (p = 
0.59). 
Table 2: Various clinical parameters in low and high groups 
when miR-150 was estimated initially 
Parameters  
Mir-150 initial < 1 
N = 35 
Mir-150 initial > 1 
N = 15 
P value 
Age (years) Mean ± S.D 39.4 ± 10.9 32.8 ± 14.5 > 0.05 
Sex n (%) 
Male 
Female 
22 (62.8) 
13 (37.2) 
10 (66.7) 
5 (33.3) 
> 0.05 
TLC initial x109/L 
Median 
Range 
9.5 
0.7-  42.3 
36 
1.68-112.58 
0.023* 
Plts initial x109/L 
Median 
Range 
40 
(2.0-211) 
33 
(2.0-290) 
0.649 
HB initial gm/dl 
Median 
Range 
7.9 
5.6-12.1 
7.3 
4.8-11.5 
0.094 
PB initial Blasts%  (mean ± S.D) 40.06 ± 27.85 58.2 ± 25.87 0.036* 
BM initial 
cellularity n(%) 
 
Normocellular 
Hypocellular 
Hypercellular 
Extrahypercellular 
9 (25.7) 
3 (8.6) 
14 (40) 
9 (25.7) 
3 (20.0) 
2 (13.3) 
9 (60.0) 
1 (6.7) 
0.362 
BM initial blast%  (mean ± S.D.) 62.6 ± 20.07 67.93 ± 20.0 0.393 
FAB classification 
n(%) 
 
M0 
M1 
M2 
M3 
M4 
M5 
M7 
Others (phenotypic) 
1 (2.9) 
7 (20) 
13 (37.1) 
1 (2.9) 
8 (22.9) 
2 (5.7) 
2 (5.7) 
1 (2.9) 
0 
1 (6.7) 
5 (33.3) 
4 (26.7) 
2 (13.3) 
0 
2 (13.3) 
1 (6.7) 
0.185 
IPT n(%) 
 
Myeloid 
Mono 
Myeloma 
Myeloid with aberrant 
Myeloid-B 
Others 
20(57.1) 
1(2.9) 
6(17.1) 
5(14.3) 
1(2.9) 
2(5.7) 
9 (60) 
0 
0 
2 (13.3) 
1 (6.7) 
3 (20) 
0.353 
FLT3 n(%) 
 
Wild 
Mutant 
NA 
26(74.3) 
5(14.3) 
4(11.8) 
8 (53.3) 
4 (26.7) 
3 (20) 
0.346 
Cytogenetics 
n(%) 
 
T (9, 22) 
T (8, 21) 
T (15, 17) 
Normal karyotype 
Others 
1(4.8) 
2(9.5) 
1(4.8) 
7(33.3) 
10(47.6) 
0 
0 
3 (27.3) 
6 (54.2) 
2 (18.2) 
0.138 
 
 
 
 
BM Cellularity  
N(%) D28  
 
 Normocellular 
 Hypocellular 
 Hypercellular 
NA 
13(52) 
9(36) 
1(4) 
2(8) 
6 (50) 
2 (16.7) 
4 (33.3) 
0 
0.067 
Blast n(%) D28 
Less than or equal 5 
More than 5 
18(75.0) 
6(25) 
9 (75) 
3 (25) 
0.05 
TLC x109/L D28 
 
Median 
Range 
2.0 
(0.1-16.3) 
4.27 
(0.56-16) 
0.023* 
HB gm/dl D28 
Median 
Range 
7.7 
(3.3-10.3) 
8.7 
(7-10) 
0.013* 
Plts x109/L D28 
 
Median 
Range 
84.5 
(2.00-579) 
333 
(5-558) 
0.014* 
PB blasts n(%) 
D28 
Equal zero 
More than 1 
16(76.2) 
5(23.8) 
7 (87.5) 
1 (12.5) 
0.50 
Response to 
treatment n(%) 
CR 
Refractory 
NA 
10(62.5) 
3(18.8) 
3(18.8) 
22 (64.7) 
6 (17.6) 
6 (17.6) 
0.98 
Relapse 
 
Relapse  
No relapse 
NA 
2(16.7) 
9(75) 
1(8.3) 
5 (19.2) 
17 (65.4) 
4 (15.4) 
0.79 
Early death  
 
Before D28 
After D28 
3(50) 
3(50) 
7 (53.8) 
6 (46.2) 
0.87 
TLC: total leucocytic count, HB: haemoglobin, PLT: platelet count, PB: peripheral blood, 
BM: bone marrow, FAB: French American British classification, IPT: immunophenotyping, 
D28: day 28 of treatment, NA: non-available, CR: complete remission, OS: overall survival. 
 
Table 2 shows a comparison between 
different clinical parameters when miR-150 was 
measured before the start of treatment. Patients were 
divided into two groups; the low expressers for the 
miR-150 group (miRNA-150 < 1) and the high 
expressers for the miR-150 group (miR-150 > 1). A 
statistically significant correlation was found between 
high miR-150 and higher initial TLC and PB blast %, 
while this significant correlation was observed with 
higher TLC, HB concentration and PLT count at D28 
(p = 0.023, 0.036, 0.023, 0.013, 0.014 respectively). A 
relation also was found between initial low miR-150 
and normocellular marrow at D28 samples but not 
reach a statistical significance (p = 0.067). 
Table 3 shows a comparison between 
different clinical and laboratory parameters in the low 
miR-150 group and the high miR-150 group when 
miR-150 was measured at D28. A statistically 
significant relation was found between low miR-150 
and myeloid phenotype (p = 0.030) and also with no 
relapse status for the patients (p = 0.035). 
Table 3: Various clinical parameters in low and high groups 
when miR-150 was estimated at D28 
Parameter 
 
 miR-150 at D28< 1 
n = 23 
miR-150 at D28> 1 
n = 8 
P value 
Age (years) Mean ± S.D 33.9 ± 10.5 38.85 ± 10.27 0.262 
Sex n (%) 
Male 
Female 
10 (45.5) 
13 (54.5) 
5 (62.5)  
3 (37.5) 
0.409   
TLC x10
9
/L 
initial 
 
Median 
Range 
10 
(1.2-42.3) 
15.95 
(1.68-65.35) 
0.963 
PLT x10
9
/L  
 
Median 
Range 
33 
(2.0-208) 
18 
(9-290) 
0.37 
HB gm/dL 
 
Median 
Range 
8.1 
(5.9-12.1) 
7.9 
(4.8-9.1) 
0.1 
PB Blasts% Median 
Range 
40 
(4-94) 
18.5 
(0-65) 
0.139 
BM cellularity 
n(%) 
 
Normocellular 
Hypocellular 
Hypercellular 
Extrahypercellular 
5 (21.7) 
2 (8.7) 
10 (43.5) 
6 (26.1) 
1 (12.5) 
3 (37.5) 
4 (50) 
0 (0) 
0.089 
FAB n (%) 
 
M0 
M1 
M2 
M3 
M4 
M7 
Other 
1 (4.3) 
4 (17.4) 
10 (43.5) 
2 (8.7) 
5 (21.7) 
0 (0) 
1 (4.3) 
0 (0) 
1 (12.5) 
1 (12.5) 
1 (12.5) 
2 (25.0) 
3 (37.5) 
0 (0) 
0.084 
IPT n (%) 
 
Myeloid 
Myelomonocytic 
Myeloid with aberrant 
Myeloid B 
Other 
15 (65.2) 
2 (8.7) 
4 (17.4) 
1 (4.3) 
1 (4.4) 
4 (50) 
0 (0) 
0 (0) 
0 (0) 
4 (50) 
0.030* 
FLT-3 n (%) 
 
Wild 
Mutant 
NA 
19 (82.6) 
4 (17.4) 
0 (0) 
7 (87.5) 
0 (0) 
1 (12.5) 
0.117 
Cytogenetics 
n (%) 
 
t(8,21) 
t(15,17) 
Normal karyotype 
Others 
2 (13.3) 
2 (13.3) 
6 (40) 
5 (33.3) 
0 (0) 
0 (0) 
4 (66.7) 
2 (33.3) 
0.524 
BM D28 
cellularity n 
(%) 
Normocellular 
Hypocellular 
Hypercellular 
9 (45) 
8 (40) 
3 (15) 
3 (37.5) 
3 (37.5) 
2 (25) 
0.817 
BM Blasts% 
D28  
 
Median 
Range 
Less than or equal 5 
More than or equal 6 
25 
(0-67) 
15 (75) 
5 (25) 
2.5 
(0-30) 
6 (75) 
2 (25) 
 
 
 
0.69 
TLC x10
9
/L at 
D28 
Median 
Range 
2.6 
(0.1-16.3) 
2.94 
(0.38-16) 
0.663 
HB gm/dL 
 at D28 
Median 
Range 
7.9 
(3.3-10) 
8 
(6.9-10.3) 
0.788 
PLT x10
9
/L at 
D28 
Median 
Range 
111.5 
(2-558) 
110 
(5-579) 
0.826 
PB blasts % 
at D28 
Equal zero 
More than or equal 1 
15 (71.4) 
6 (28.6) 
7 (100) 
0 
0.1 
Response to 
treatment 
Refractory 
CR 
4 (18.2) 
18 (81.8) 
2 (25) 
6 (71.475) 
0.98 
Relapse 
status 
No relapse 
Relapse 
16 (84.2) 
3 (15.8) 
3 (42.9) 
4 (57.1) 
0.035* 
Early death  Before D28 
After D28 
2 (22.2) 
6 (75) 
1 (100) 
0 (100) 
0.13 
TLC: total leucocytic count, HB: hemoglobin, PLT: platelet count, PB: peripheral blood, 
BM: bone marrow, FAB: French American British classification, IPT: immunophenotyping, 
D28: day 28 of treatment, NA: non-available, CR: complete remission, OS: overall survival, 
RFS: Relapse-free survival. 
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Survival analysis 
Kaplan-Meier survival curves were used to 
estimate overall survival (OS) and relapse-free 
survival (RFS) in the AML patients which are shown in 
figures (3A and 3B) and are summarised in Table 4.  
A)
 
B)
 
Figure 3: A) Overall survival of AML patients; B) relapse-free 
survival of AML patients 
 
Moreover, there was no difference in the 
overall survival between the low and the high miR-150 
groups when measured initially before the start of 
treatment (Figure 4A). Also, there was no difference in 
the overall survival between the low and the high miR-
150 groups when measured at D28 as illustrated in 
(Figure 4B).  
A) 
 
B)
 
Figure 4: A) Overall survival compared between high and low miR-
150 when measured initially; B) Overall survival compared between 
high and low miR-150 when measured at follow up 
Table 4: Overall survival and disease/relapse-free survival 
Parameter 
 
AML patients 
 
Mean No of dead/relapse 
n (%) 
No of alive/ 
relapse-free 
n (%) 
Overall survival (time 
/month) (95%CI) 
N = 47 
 
17.73 (14.2-
21.21) 
17 (36.17) 30 (63.8) 
Disease/relapse free 
survival (95%CI) 
N = 27 12.82 (8.56-
17.07) 
16 (59.3) 11 (40.7) 
 
We used in the silico analysis to predict the 
target genes, as shown in Table 5. We identified the 
most promising potential target genes and highly 
significant enrichment pathways for miR-150. The 
main target genes are ACOX1, BDNF, RAPGEF3, 
FGF7, FGF12, PIK3R3, TNF, E2F3, SMAD4, STAT5B 
which are involved in cAMP, MAPK, ErbB, mTOR, 
chronic myeloid leukaemia signalling pathway and 
pathway in cancer.  
Most of the gene ontology (GO) annotations 
were associated with cell process, regulation of 
biological process, regulation of cell communication, 
intracellular signalling cascade, localisation and others 
Figure 5.  
 
Table 5: Prediction of the target genes miR-150 and its 
pathways 
 Target genes Pathways 
 
 
 
 
miR-150 
 
 
 
 
 
 
ACOX1, PPARA, ADCY1, ADCY2, ADCY5, 
ADCY6, GABBR1, CNGB1, ADORA1, 
ATP2B1, BDNF, ATP2B3, ATP2B4, GRIN2B, 
TIAM1, PDE4A, PAK1, RAPGEF3,  
cAMP signaling pathway 
FGF7, ZAK, PDGFB, FGF9, GNA12, FGF12, 
MAX, BDNF, MAPT, PAK1, FGF1, IL1A, 
AKT3, AKT2, PRKCA, BRAF, CACNG8, 
TP53, CACNG4, CACNG2, PRKCB,  
MAPK signaling pathway 
GRB2, CAMK2G, STAT5B, ELK1, PAK3, 
CAMK2B, SHC1, PAK1, SHC3, PIK3R3, 
AKT3, PIK3R1, PIK3R2, SHC4, AKT2 
ErbB signaling pathway 
PRKCA, TNF, BRAF, STK11, PIK3CB, IGF1, 
RICTOR, PRKCB, EIF4B, RPS6KA6, 
RPS6KA3, AKT1S1, TSC1, ULK1, ULK2, 
ULK3, PRKAA2, PIK3R3, AKT3, PIK3R1, 
AKT2, PIK3R2 
mTOR signaling pathway 
E2F3, BRAF, GRB2, PIK3CB, TGFBR1, 
CBL, STAT5B, TP53, SMAD4, CDK4, CBLB, 
CCND1, CDKN1B, ARAF, MDM2, SHC1, 
PIK3R3, SHC3, CRK, PIK3R1, AKT3, AKT2, 
PIK3R2, SHC4 
Chronic myeloid leukemia 
signaling pathway  
ADCY1, PPARD, E2F3, ADCY2, FGF7, 
PDGFB, FGF9, ADCY5, ADCY6, STAT5B, 
GNA12, SPI1, FGF12, CTNNB1, MAX, 
PAX8, SLC2A1, FGF1 
Pathway in cancer 
 
 
 
Discussion 
 
The miRNA network is highly redundant, as a 
single miRNA could have multiple target mRNAs, and 
on the other hand, a single mRNA may be targeted by 
many miRNAs [20]. Many miRNAs have been shown 
to be involved in a myriad of cellular processes which 
include differentiation, apoptosis, metabolism and 
development [21]. Physiologically, as well as 
pathologically, miRNAs have been reported to play 
roles in cancers, inflammatory responses, diabetes 
and autoimmune diseases [22].  
Figure 5: Functional gene ontology terms for miR-150 target genes 
 
 In this work, we investigated the role of miR-
150 level in de novo adult AML; where we found a 
significantly lower level in patients when compared to 
controls (P = 0.012). These results are supported by 
the clarification of a previously uncharacterized role 
for miR-150 in promoting myeloid differentiation, 
where Morris et al. [25], demonstrated that low miR-
150 expression contributes to the leukemic phenotype 
in various AML subtypes and BC of CML. Also, 
Fayyad-Kazan et al. [14] and Wang et al. [23], 
reported similar results to ours, where they found 
lower miR-150 expression in AML patients as 
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compared to controls (P = 0.0026, P = 0.006 
respectively). Also, Xu DD et al. reported that miR-150 
was downregulated in leukaemia stem cells (LSCs; 
CD34+CD38- cells) and clinical samples. Ectopic 
expression of miR-150 suppressed the LSCs 
biological behaviours, both in vitro and in vivo by its 
effect on Nanog signalling pathway [24]. 
Similarly, the expression levels of miR-150 
were decreased in AML cases as in a study by Morris 
et al. [12], and overexpression of miR-150 promoted 
myeloid differentiation of cancer cells and suppressed 
their proliferation [25]. Also, Fayyad-Kazan et al. [14] 
reported that in a recent study, plasma levels of 
tumour necrosis factor alpha, interleukin-10, and 
interleukin-18, which all have a sequence, 
complementary to miR-150, were negatively 
correlated with the plasma levels of miR-150. This 
could impact on the immune system response to 
leukaemias. These data revealed that miR-150 could 
be a promising biomarker for AML at diagnosis and 
suggest that microRNA expression signature in 
plasma can serve as a valuable diagnostic and 
potential prognostic marker for human AML. 
MiR-150 was measured twice, first; before the 
start of treatment, then; at D28 after induction 
chemotherapy for the 31 cases that they're follow up 
samples could be reached, the comparison in 
between did not reveal any statistical significance. 
Also, the comparison between levels of MiR-150 
before treatment and at D28 for cases that undergo 
complete remission did not reveal any statistical 
significance. So, our results showed no difference 
between miRNA levels initially and at D28 with and 
without discrimination of the response to treatment. 
This was in contrast to Wang et al. [23] and Fayyad-
Kazan et al. [14], who reported that there was up-
regulation of miR-150 level in AML patients who 
achieved CR reaching the level of controls (P < 0.01) 
compared to its down-regulation before treatment. In 
our study, this could be explained by the fact that 
there was no difference in miRNA level between the 
cytogenetically good and bad prognostic groups of 
patients in our study, in contrast to Wang et al. [23]
 
and Morris et al. [25], who reported a significant 
decrease in miRNA level in the poor and intermediate 
risk cytogenetics groups as compared to the favorable 
group.  
Our patients were divided into two groups; the 
low expressers for the miR-150 group (miR-150 < 1) 
and the high expressers for the miR-150 group (miR-
150 > 1). The correlation between plasma miR-150 
levels and clinicopathological data were verified. A 
statistically significant correlation was found between 
high miR-150 and both a higher initial TLC and PB 
blast % and with a higher TLC, HB and PLT count at 
D28 (p = 0.023, 0.036, 0.023, 0.013, 0.014 
respectively). A relation was also found between low 
miR-150 and normocellular marrow at D28 samples 
but could not reach a statistical significance (p = 
0.067). However, no significance could be recorded 
with others. Wang et al., [23] reported a significant 
correlation with the percentage of initial BM blast% (P 
= 0.020). However no significant difference was found 
with initial TLC, PLT number (P > 0.05). He also found 
a significant relation with FAB classification (P = 
0.013) and cytogenetics (P = 0.012). However, no 
significant difference was found between the level of 
miR-150 and gender, age and extramedullary disease 
(P > 0.05) 
Wang et al. [23], reported that AML patients 
with M5 subtype had a lower serum miR-150 level 
than those with other subtypes including M0, M1, M2 
and M4 (P < 0.01). Our study included only 2 patients 
with M5, so, monocytic leukaemias (M4 and M5) in 
our study were summed up together and showed 
lower miR-150 level than other FAB subtypes, 
although with no statistically significant difference. We 
accordingly expect that with increasing the number of 
patients, comparable results could be obtained.  
We found no statistically significant relation 
regarding Flt-3 mutational status between the high 
and low miR-150 groups; either initially or at D28. Our 
results are supported by Jiang et al. [13], who 
reported that forced expression of miR-150, reduced 
the levels of Flt-3 to 40-65%. Their results indicated 
that Flt3 functions as a direct target of miR-150 in 
regulating leukemic cell self-renewal and at least in 
part, responsible for the inhibitory effects of forced 
expression of miR-150 on leukemogenesis [30].  
As regarding the prognostic value of initial 
plasma miR-150 in AML adult patients, our follow up 
data did not reveal any relation between different 
levels of our target miR-150 and either; the spectrum 
of response to treatment involving CR and refractory 
cases; those undergo relapse or not, or those undergo 
early death before D28 or not. But revealed a 
statistically significant relationship between lower 
levels of miR-150 at D28 and cases that did not show 
relapse (P = 0.035). Also, our survival analysis data 
revealed no significant relation between levels of miR-
150 and overall or relapse-free survival, which was 
inconsistent to Wang et al. [23], who showed that AML 
patients in his low miR-150 group had significantly 
shorter five-year overall survival (P = 0.009) and 
event-free survival (P = 0.004) than patients in his 
high miR-150 group.  
As regard target genes pathway analysis, it 
showed that the predicted target genes might play 
their roles through cellular pathways. Those target 
genes are implicated in proliferation, adhesion, and 
apoptosis. The main target gene of miR-150 included 
AKT2, CBL, and PRKCA [29].  
Mir-150 targets and downregulates AKT2 
gene that is involved in Erb, MAPK, CML and mTOR 
signalling pathway, resulting in reduced the 
phosphorylated levels of AKtser473/4. Subsequently, 
this increases the levels of tumour suppressor genes 
such as Bim and P53, which leads to telomerase 
activation and immortalisation of cancer cells [26]. 
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Also, CBL gene is implicated in AML signalling 
pathway and downregulated by miR-150 [27], [28]. 
The α isoform of Protein kinase C (PKCα), 
has been recognised as a tumour growth regulator in 
different types of cancers. Targeting PKCα-mediated 
signal transduction induces cell death in AML cells 
inhibiting BCL-2 phosphorylation and blocking ERK 
activation [29]. Overexpression of miR-150 
significantly suppressed the endogenous expression 
of PKCα, and luciferase reporter/mutagenesis assays 
confirmed that PRKCA is a transcriptional target of 
miR-150 [31].  
In conclusion, miRNAs have emerged as a 
class of gene expression important regulators 
contributing to AML pathogenesis and as potential 
biomarkers [32]. 
We conclude that miR-150 functions as a 
pivotal gatekeeper in inhibiting cell transformation and 
functions as a tumour suppressor and its repression 
are required for leukemogenesis. Moreover, miRNAs 
regulate different mRNA targets, and their modulation 
can represent a potential therapeutic target in 
combination with current chemotherapy in the 
eradication of leukemic progenitors. 
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